Thiamine pyrophosphate (TPP) is the active metabolite of thiamine. This study aimed to
investigate the effects of thiamine and TPP on cisplatin-induced peripheral neuropathic
pain (PNP). Male albino Wistar type Rattus norvegicus were divided into
six groups (n=6) that received 2 mg/kg cisplatin (CIS), 25 mg/kg thiamine (TM), 2 mg/kg
cisplatin+25 mg/kg thiamine (CTM), 25 mg/kg TPP (TPP), 2 mg/kg cisplatin+25 mg/kg TPP
(CTPP), or distilled water (healthy group; HG) for 8 days intraperitoneally. Analgesic
effect was measured with a Basile Algesimeter. IL-1β, malondialdehyde
(MDA), total glutathione (tGSH), thiamine, and TPP were determined in blood samples.
Histopathological examinations were performed on removed sciatic nerves. The percent
analgesic effects of the CTM and CTPP groups were calculated to be 21.3% and 82.9%,
respectively. Increased production of IL-1β and MDA by cisplatin was
inhibited by TPP, while it was not inhibited by thiamine. Conversion of thiamine to TPP
significantly decreased in the CIS group. Histopathological and biochemical investigations
demonstrated that hyperalgesia and sciatic nerve damage developed in the CIS and CTM
groups with low TPP levels. These results indicate that cisplatin inhibits the formation
of TPP from thiamine, leading to severe PNP. This finding suggests that TPP may be more
beneficial than thiamine for the treatment of cisplatin-induced PNP.